Business Context and Reporting Period
This Form 8-K was filed by Avista Healthcare Public Acquisition Corp. (AHPAC) on February 9, 2018. The filing reports on amendments to the proposed business combination between AHPAC and Envigo International Holdings, Inc. (Envigo). Note: The input metadata references "Organogenesis Holdings Inc.," but the filing text explicitly concerns AHPAC and Envigo.
Key Financial Metrics
The filing does not provide standard financial statements (revenue, profit, cash flow, or margins) for the reporting period. The primary financial disclosure relates to the transaction structure:
- Consideration Adjustment: The aggregate consideration payable to Selling Equityholders is reduced by approximately $79 million.
- Share Surrender: Class B Holders will surrender an aggregate of 4,715,576 Class B Shares and 4,100,000 Private Placement Warrants immediately prior to the consummation of the merger.
Material Changes Versus Prior Period
The filing details Amendment No. 4 to the Transaction Agreement, executed on February 9, 2018. This amendment modifies the terms previously established in Amendments 1, 2, and 3 (dated November 2017 through January 2018). The material change is the reduction in the total purchase price for Envigo and the corresponding increase in the number of shares and warrants surrendered by the Parent Sponsor and Class B Holders.
Guidance, Outlook, and Risks
- Transaction Status: The Transaction Agreement remains in full force and effect, subject to the modifications in Amendment No. 4.
- Shareholder Action: AHPAC has filed a preliminary proxy statement and will file a definitive proxy statement for shareholder voting on the business combination.
- Risks and Contingencies: The filing includes a standard disclaimer that the report does not constitute an offer to sell securities. The transaction is contingent upon shareholder approval and regulatory filings.
Important Facts for Investor Verification
- Verify the final terms of the definitive proxy statement regarding the $79 million reduction in consideration.
- Confirm the exact number of shares and warrants to be surrendered by the Class B Holders (4,715,576 shares and 4,100,000 warrants).
- Review the preliminary and definitive proxy statements for details on the record date for voting and the timeline for the merger consummation.
- Note that the filing entity is Avista Healthcare Public Acquisition Corp., not Organogenesis Holdings Inc.